Cartesian Therapeutics, Inc.
News
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Recommendation of "Moderate Buy" by Analysts
Ticker Report Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm...\n more…
Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis
Globe Newswire IND filing for Phase 2 pediatric basket study on track for year-endGAITHERSBURG, Md., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the Company ), a...\n more…
Cartesian Therapeutics Announces New Employment Inducement Grant
Globe Newswire GAITHERSBURG, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the Company ), a clinical-stage biotechnology company developing mRNA cell therapies for the...\n more…
Cartesian Therapeutics (NASDAQ:RNAC) Stock Rating Reaffirmed by HC Wainwright
Ticker Report Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report)s stock had its "buy" rating restated by research analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They...\n more…
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
Globe Newswire Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies GAITHERSBURG, Md., Sept...\n more…